Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARL | Q9H300 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4401949 | 0.92 | KDM4E (0.30) | — | |
| SCHEMBL10030211 | 0.86 | — | — | |
| SCHEMBL19285808 | 0.78 | TIMP3 (0.52) | — | |
| SCHEMBL4402100 | 0.76 | CASP6 (0.59) | — | |
| SCHEMBL19878139 | 0.76 | ENPP2 (0.38) | — | |
| SCHEMBL4403315 | 0.76 | APEX1 (0.39) | — | |
| SCHEMBL4402086 | 0.75 | CASP6 (0.40) | PARL | |
| SCHEMBL15489095 | 0.72 | — | — | |
| SCHEMBL10030202 | 0.72 | HPGD (0.41) | — | |
| SCHEMBL4399520 | 0.72 | ALDH1A1 (0.54) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2252584-B1 | COMPOUNDS AND METHODS FOR RAPID LABELING OF N-GLYCANS | PROZYME INC (US) | 2016-12-07 | — | — | EP | disclosed |
| US-8445292-B2 | Compounds and methods for rapid labeling of N-glycans | PROZYME, INC. (US) | 2013-05-21 | — | — | US | disclosed |
| US-20120107942-A1 | COMPOUNDS AND METHODS FOR RAPID LABELING OF N-GLYCANS | PROZYME, INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8124792-B2 | Compounds and methods for rapid labeling of N-glycans | PROZYME, INC. (US) | 2012-02-28 | — | — | US | disclosed |
| US-20090258437-A1 | COMPOUNDS AND METHODS FOR RAPID LABELING OF N-GLYCANS | PROZYME, INC. (US) | 2009-10-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090258437-A1 | COMPOUNDS AND METHODS FOR RAPID LABELING OF N-GLYCANS | B3GNT2, FUT5, FUT6 | PARL 3779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.